NEWS

Taiwan Bio Therapeutics and TRACT Therapeutics Announce Successful Transfer of TRACT’s Regulatory T Cell Platform Technology to Taiwan Bio’s Manufacturing Facility

August 12, 2024 08:00 AM Eastern Daylight Time TAIPEI, Taiwan & CHICAGO--Taiwan Bio Therapeutics, Inc. and TRACT Therapeutics, Inc. are...

Aug 12, 2024

[Chicago, IL and Taipei, Taiwan- 12Mar2024] - TRACT Therapeutics and Taiwan Bio Therapeutics are pleased to announce a poster...

Mar 12, 2024

[Chicago, IL and Taipei, Taiwan – 06Dec2023] – Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to...

Dec 6, 2023

TRACT Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company

Nov 19, 2020

SCIENTIFIC REPORTS, A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants” April...

Sep 1, 2019

TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment...

Jun 25, 2016

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients Download the...

Jun 24, 2016

TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient’s Immune Cells to Prevent Organ Rejection CHICAGO -...

May 12, 2016

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in de novo living donor kidney transplant recipients. Download the full...

Feb 17, 2016

TRACT Therapeutics, Inc. Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection Safety Data Presented...

Aug 16, 2015

International Society for Cellular Therapy, Miltenyi Biotec Corporate Symposium, May 27, 2015, Las Vegas, NV Ann LeFever, PhD to present...

Mar 4, 2015

“A kidney transplant that lasts for life. It’s the ultimate goal. But the drugs that keep a donor organ going also pose the greatest...

Feb 26, 2015